Format

Send to

Choose Destination
Br J Pharmacol. 2014 Apr;171(8):2029-50. doi: 10.1111/bph.12461.

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Author information

1
Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY, USA.

Abstract

A decline in energy is common in aging, and the restoration of mitochondrial bioenergetics may offer a common approach for the treatment of numerous age-associated diseases. Cardiolipin is a unique phospholipid that is exclusively expressed on the inner mitochondrial membrane where it plays an important structural role in cristae formation and the organization of the respiratory complexes into supercomplexes for optimal oxidative phosphorylation. The interaction between cardiolipin and cytochrome c determines whether cytochrome c acts as an electron carrier or peroxidase. Cardiolipin peroxidation and depletion have been reported in a variety of pathological conditions associated with energy deficiency, and cardiolipin has been identified as a target for drug development. This review focuses on the discovery and development of the first cardiolipin-protective compound as a therapeutic agent. SS-31 is a member of the Szeto-Schiller (SS) peptides known to selectively target the inner mitochondrial membrane. SS-31 binds selectively to cardiolipin via electrostatic and hydrophobic interactions. By interacting with cardiolipin, SS-31 prevents cardiolipin from converting cytochrome c into a peroxidase while protecting its electron carrying function. As a result, SS-31 protects the structure of mitochondrial cristae and promotes oxidative phosphorylation. SS-31 represents a new class of compounds that can recharge the cellular powerhouse and restore bioenergetics. Extensive animal studies have shown that targeting such a fundamental mechanism can benefit highly complex diseases that share a common pathogenesis of bioenergetics failure. This review summarizes the mechanisms of action and therapeutic potential of SS-31 and provides an update of its clinical development programme.

KEYWORDS:

SS-31; Szeto-Schiller peptides; bendavia; cytochrome c; cytochrome c peroxidase; mitochondria cristae; mitochondrial permeability transition; oxidative stress; reactive oxygen species

PMID:
24117165
PMCID:
PMC3976620
DOI:
10.1111/bph.12461
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center